Phase 2 Completed N=20 Treatment

Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer

Pancreatic Cancer

Source: ClinicalTrials.gov NCT00350142 ↗

Enrolled (actual)

Serious AEs

5.0%

Results posted

Aug 2014

Primary outcomePrimary: Rate of Local Control — 15 participants

Summary

This study will assess the efficacy of treating locally advanced pancreatic cancer using Stereotactic Body Radiotherapy (using Trilogy) and Gemcitabine

Outcome Measures

Outcome	Result	p-value
PRIMARY Rate of Local Control	15	—
SECONDARY Median Overall Survival Time	11.8	—

Eligibility Criteria

Inclusion Criteria:- Pancreatic tumors not to exceed 10 cm in greatest axial dimension

Histologically confirmed malignancies of the pancreas
Unresectable by CT criteria or exploratory laparotomy or laparoscopy
Patients with metastatic disease may be treated if they are symptomatic from the primary tumor
Performance status of 0, 1, or 2
No chemotherapy two weeks prior or two weeks following radiosurgery

Exclusion Criteria

patients who have had prior radiotherapy to upper abdomen
patients receiving any prior pancreatic cancer therapy
children, pregnant, and breastfeeding women, and lab personnel are excluded
uncontrolled intercurrent illnesses
any concurrent malignancy

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00350142). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.